Cook gets US nod for pivotal PATENCY trial:
This article was originally published in Clinica
Executive Summary
The US FDA has conditionally approved Cook's pivotal trial of its paclitaxel- eluting coronary stent for combating restenosis. PATENCY study, which will begin enrolling 200 patients at 20 sites immediately, is expected to keep Cook on track to launch its Logic PTX drug-eluting stent in the US next year, says the Bloomington, Indiana firm. In a separate announcement, Cook said it had gained US go-ahead to enrol 100 patients at 10 institutions in a randomised pilot study to assess its device as a treatment for in-stent restenosis.
You may also be interested in...
Cosmetic And Personal Care Trademark Review: 16 April
Personal care and cosmetic product trademark filings compiled from the Official Gazette of the US Patent and Trademark Office, Class 3.
Health And Wellness Weekly Trademarks Review: 16 April
Trademarks are registered and published for opposition with the US Patent and Trademark Office and are published weekly in the agency's Official Gazette.
Beauty Packaging Producers: July Marks Registration Deadline With PRO In Three States
Companies considered producers of single-use packaging in Oregon, Colorado and California must register with Circular Action Alliance, the leading (and currently only) producer responsibility organization, by 1 July 2024 under new state recycling laws.